Healthcare Industry News: antibiotic
News Release - July 15, 2015
Entasis Appoints Robin David Isaacs as Chief Medical OfficerWALTHAM, Mass.--(Healthcare Sales & Marketing Network)--Entasis Therapeutics, a company leveraging its expertise and a unique pathogen-targeted approach to develop and advance novel antibacterials, today announced the appointment of Robin David Isaacs, M.D., as Chief Medical Officer. Dr. Isaacs has extensive experience as a pharmaceutical executive in the development and launch of vaccine and infectious disease products.
“Dr. Isaacs’ experience in clinical research, global clinical development, and life cycle management of infectious disease products is extremely valuable as we approach significant milestones with our lead candidate, ETX0914, and advance our preclinical pipeline,” said Manos Perros, Ph.D., President and Chief Executive Officer of Entasis. “The expertise that Dr. Isaacs brings complements the strengths of our management team, enhancing our efforts to deliver novel cures to patients who lack other treatment options.”
Dr. Isaacs has held positions of increasing responsibility at Merck & Co., Inc. Most recently, he held the title of Vice President and Therapeutic Area Head, Vaccine Clinical Research. During his 18 years at Merck, Dr. Isaacs was involved with the worldwide development, regulatory submission, and approval of many anti-infective, antiviral, and vaccine products, including CRIXIVAN®, STOCRIN®, INVANZ®, ISENTRESS®, GARDASIL®, VICTRELIS®, ZOSTAVAX®, ROTATEQ®, and GARDASIL®9.
“With significant milestones ahead and the opportunity to develop meaningful new treatments, this is an exciting time to be joining Entasis,” said Dr. Isaacs. “ETX0914, which is a first-in-class novel oral antibiotic currently in Phase 2 for the treatment of uncomplicated gonorrhea, has been designated a Qualified Infectious Disease Product (QIDP) by the FDA and awarded Fast-Track status. I am thrilled to be a part of a team exploring new therapies in a directed, focused way to introduce medicines with improved efficacy for these very challenging pathogens.”
About Entasis Therapeutics Inc.
Entasis Therapeutics is developing a portfolio of innovative cures for serious drug-resistant bacterial infections, a global health crisis affecting the lives of millions of patients. Our deep pipeline of novel clinical and preclinical antibacterial programs is designed to revolutionize the way physicians treat serious bacterial diseases. www.entasistx.com
Source: Entasis Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.